Age-Related Hormone Decline
Also known as: Hormonal Aging · Endocrine Senescence
Age-related hormone decline is the gradual, predictable downshift of testosterone, estradiol, growth hormone signaling, DHEA, and thyroid axis sensitivity that begins in midlife. It is a physiological pattern — not a single disease — and is the substrate underneath many adult quality-of-life changes.
What you need to know
From roughly the mid-30s onward, multiple endocrine axes decline at predictable rates: testosterone (~1%/yr in men), DHEA, growth hormone pulsatility, ovarian estradiol production (women), and thyroid sensitivity. The result is a slow drift in body composition, recovery, libido, mood, and cognitive resilience. The optimization-medicine framing is preventative: track baseline biomarkers earlier, recalibrate against a defined cadence, and intervene where symptoms and biomarkers converge — not based on age alone.
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Treatment medications
Bring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.